Homepage

MPN Research Foundation is pleased to share the news of the US FDA approval of momelotinib for the treatment of myelofibrosis patients with anemia whether they have had prior treatment or not. Let’s break down what the approval of this new drug means for those impacted by MPNs: • Treatment options are expanding. Janus kinase (JAK) inhibitors… Read More »What to Know About the FDA Approval of momelotinib

“From the outset, we recognized that outstanding care of MPN patients required not just hematologists (who would be their primary doctors) but also the participation of other specialists who had expertise in the complications of MPNs, such as cardiologists, neurologists, vascular surgeons, interventional radiologists, dermatologists, infectious disease specialists, gastroenterologists, and rheumatologists.”         … Read More »Q&A with MPN Pioneer Andrew Schafer, MD

Philadelphia-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematologic malignancies characterized by the abnormal proliferation of blood cells in the bone marrow. MPNs cause significant morbidity in the form of burdensome symptoms, potentially fatal cardiovascular complications, progression to more aggressive disease, and over time, can evolve to… Read More »Current and Emerging Therapies